Aberrant DNA methylation of acute myeloid leukemia and colorectal cancer in a Chinese pedigree with a MLL3 germline mutation
Unlike genetic aberrations, epigenetic alterations do not modify the deoxyribonucleic acid (DNA) coding sequence and can be reversed pharmacologically. Identifying a particular epigenetic alteration such as abnormal DNA methylation may provide better understanding of cancers and improve current therapy. In a Chinese pedigree with colorectal carcinoma and acute myeloid leukemia, we examined the genome-wide DNA methylation level of cases and explored the role of methylation in pathogenesis and progression. DNA methylation status in the four cases, which all harbor a MLL3 germline mutation, differed from that of the normal control, and hypermethylation was more prevalent. Also, more CpG sites were hypermethylated in the acute-phase AML patient than in the AML patient in remission. Fifty-nine hyper- or hypomethylated genes were identified as common to all four cases. Genome-wide DNA methylation analysis demonstrated that differentially methylated sites among acute myeloid leukemia and colorectal carcinoma cases and the control were in both promoters (CpG island) and gene body regions (shelf/shore areas). Hypermethylation was more prevalent in cancer cases. The study supports the suggestion that the level of DNA methylation changes in AML progression.
KeywordsAcute myeloid leukemia Colorectal cancer DNA methylation
We thank all subjects who donated blood samples for genetic research purposes. This work was supported in part by grant 81070576 from the National Natural Science Foundation of China and grant 12JCZDJC24700 from Tianjin Municipal Science and Technology Commission to W.-D.L.; and by National Natural Science Foundation of China (NSFC 81270605,30971066,81470324), Third Military Medical University Clinical and Science Great Fund Project (2102XLC03), Chongqing Postgraduate Education Reform Project (yjg123114), Chongqing Natural Science Fund Project (CSTC’2008BA5001), and Military Emphasis Medical Scientific Research Project Fund to J.-P.C.
Compliance with ethical standards
Conflicts of interest
- 1.Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol. 2000;183(2):145–54. doi: 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V.CrossRefPubMedGoogle Scholar
- 13.Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood. 2012;120(18):e83–92. doi: 10.1182/blood-2011-12-401471. CrossRefPubMedGoogle Scholar
- 18.Huhn S, Bevier M, Pardini B, Naccarati A, Vodickova L, Novotny J, et al. Colorectal cancer risk and patients’ survival: influence of polymorphisms in genes somatically mutated in colorectal tumors. Cancer Causes Control CCC. 2014;25(6):759–69. doi: 10.1007/s10552-014-0379-1. CrossRefPubMedGoogle Scholar
- 23.Lou S, Lee HM, Qin H, Li JW, Gao Z, Liu X, et al. Whole-genome bisulfite sequencing of multiple individuals reveals complementary roles of promoter and gene body methylation in transcriptional regulation. Genome Biol. 2014;15(7):408. doi: 10.1186/s13059-014-0408-0. CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Kloten V, Rose M, Kaspar S, von Stillfried S, Knuchel R, Dahl E. Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype. Epigenetics Off J DNA Methylation Soc. 2014;9(9):1290–301. doi: 10.4161/epi.32089. CrossRefGoogle Scholar
- 30.Li Q, Kopecky KJ, Mohan A, Willman CL, Appelbaum FR, Weick JK, et al. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5(5):1077–84.Google Scholar
- 39.Musialik E, Bujko M, Kober P, Wypych A, Gawle-Krawczyk K, Matysiak M, et al. Promoter methylation and expression levels of selected hematopoietic genes in pediatric B-cell acute lymphoblastic leukemia. Blood Res. 2015;50(1):26–32. doi: 10.5045/br.2015.50.1.26. CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Shao LL, Fan J, Wang R, Feng LL, Zhen CQ, Sui XH, et al. Expression of TFPI-2 gene and its promoter methylation in acute myeloid leukemia. Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = J Exp Hematol / Chin Assoc Pathophysiol. 2014;22(4):920–6. doi: 10.7534/j.issn.1009-2137.2014.04.008. Google Scholar